NCT02784613View on ClinicalTrials.gov

Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

February 7, 2017

Study Completion Date

April 17, 2017

Conditions
Vulvovaginal AtrophyDyspareunia
Interventions
DRUG

Ospemifene

FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia

Trial Locations (1)

92120

San Diego Sexual Medicine, San Diego

All Listed Sponsors
lead

Sue Goldstein

OTHER

NCT02784613 - Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA | Biotech Hunter | Biotech Hunter